

Diving into Dizziness – A Diagnosis of Autoimmune Autonomic Ganglionopathy

Celine Zhou MD, Shadi Dowlatshahi MD, MSc Department of Medicine, Oregon Health & Science University, Portland OR

INTRODUCTION

Orthostatic hypotension

- A common complaint in both inpatient and outpatient settings
- Multiple etiologies incl. medication-induced, hypovolemia, diabetic dysautonomia, adrenal insufficiency, paraneoplastic, etc.

CASE DESCRIPTION

- 55 year old male presented with 2 months of severe symptomatic orthostatic hypotension, new onset constipation, progressive weakness and 50lbs unintentional weight loss
- No symptomatic improvement despite multiple fluid challenges, high doses of midodrine & fludrocortisone during recent outside admissions
- PMH:** poorly controlled T2DM, peripheral neuropathy, resected GIST tumor
- Vitals:**
 - Laying – BP 165/107, HR 65
 - Sitting – BP 105/62, HR 107
 - Standing – BP 129/89, HR 118 (could not stand >10 seconds)
- Exam** – strength 5/5 diffusely, normal muscle tone, decreased sensation to light touch in bilateral feet, distal > proximal muscle wasting, absent lower extremity reflexes
- Workup**
 - A1c 10%
 - Normal cortisol, TSH, B12, SPEP, UPEP
 - Normal TTE, telemetry
 - Negative CT A/P, PET scan
 - Fat pad biopsy negative for amyloid deposition
 - EMG: mild-moderate diffuse axonal sensory neuropathy
 - Paraneoplastic panel: +alpha-3 gnAChR antibodies
- Diagnosed with autoimmune autonomic ganglionopathy (AAG) based on autonomic symptoms and +gnAChR antibodies
- Started on IVIG 0.5 mg/kg/day with some improvement of reflexes and orthostatic blood pressures

DISCUSSION

Disorder	Associated Features	Comments	Diagnostic Tests
Diabetes	Usually first noticed associated with general autonomic dysfunction; orthostatic hypotension may occur early in clinical course after autonomic manifestations (e.g. orthostatic hypotension, diarrhea, constipation, urinary retention, and erectile dysfunction)	Other common cause of autonomic dysfunction in developed countries	Fasting blood glucose and glycosylated hemoglobin (HbA1c)
Hereditary amyloidoses (familial amyloid polyneuropathy)	Usually associated with generalized polyneuropathy, with prominent small fiber (pain and temperature) abnormalities, often as isolated conditions. include rapid lateral spread (often after early medication), orthostatic hypotension, and conduction abnormalities, visceral organics, and increased autonomic pressures. subcutaneous deposits may be present. diarrhea and weight loss are common. neuroglycopenia is not present.	Develops in the last 10-20 decade of life, characterized by deposition of amyloid fibrils (beta-2 microglobulin in sporadic, prion protein in endemically transmitted forms), and neural excitation; most common amyloid precursor is mutant transthyretin; specific cases may be common; mutation in gene encoding for apolipoprotein A-II, fibrinogen Aa, lysozyme, and gelsolin also give rise to amyloidoses	Assessment of for aspirate or rectal or gingival biopsy specimens for amyloid deposits; genetic testing
Primary amyloidoses (AL amyloidosis, immunoglobulin light chain-associated)	Usually associated with generalized polyneuropathy, with prominent small fiber (pain and temperature) abnormalities, often as isolated conditions. include rapid lateral spread (often after early medication), orthostatic hypotension, and conduction abnormalities, visceral organics, and increased autonomic pressures. subcutaneous deposits may be present. diarrhea and weight loss are common. neuroglycopenia is not present.	Occurs in the last 10-20 decade (50% occur by age 70); associated with amyloid fibrils (immunoglobulin light chain) deposited in various organs; orthostatic hypotension, and conduction abnormalities, visceral organics, and increased autonomic pressures. subcutaneous deposits may be present. diarrhea and weight loss are common. neuroglycopenia is not present.	Assessment of for aspirate or rectal or gingival biopsy specimens for amyloid deposits; immunohistochemistry of blood and urine
HSMN type II (also called familial dysautonomia)	Insensitivity to pain and temperature stimuli; loss of sweating, constipation, absence of tears (due to dry eye), hyporeactive carotid and vagal reflexes, and absence of tongue flicking (PRN)	An autosomal recessive disorder seen primarily in Ashkenazi Jewish children	Tests for a coding mutation in the following autonomic protein gene: HSN2A1, which is present in 99.9% of patients
Idiopathic immune-mediated autonomic neuropathy	Idiopathic immune-mediated autonomic neuropathy	May respond to immunomodulating therapy	Tests for existing ganglionic acetylcholine receptor antibodies, which are present in some patients
Sjögren's syndrome	Sicca syndrome, because of dysfunction after lacrimal and salivary gland inflammation	Autonomic manifestations may be present with initial diagnosis	Tests for anti-AChR (5A) and anti-LA (5B) antibodies
Paraneoplastic autonomic neuropathy	Neurologic features of underlying cancer may be first manifestation of a cancer	Occurs most often in patients with small cell lung cancer; also seen in non-small-cell lung cancer, various forms of gastrointestinal tract, prostate, breast, bladder, kidney, pancreas, testis, and ovary	Tests for anti-α antibodies (type 1 anti-neuronal nuclear antibodies (PNSN-1), which are most prevalent type 2) Paraneoplastic antibodies (PCA-1), and cell surface receptor antibody protein 3 (CRMP-1), which may also be present

Figure 1: Neurogenic orthostatic hypotension caused by peripheral autonomic disorders




Figure 2: Mechanism of Anti-gnAChR Ab affecting sympathetic and parasympathetic nervous systems in AAG

DISCUSSION

- AAG** – rare paraneoplastic or idiopathic condition with acquired subacute dysautonomia
- 50% of patients have ganglionic nicotinic acetylcholine receptor antibodies
- Clinical manifestations
 - Sympathetic – syncope, anhidrosis, **orthostatic hypotension**
 - Parasympathetic – urinary retention, dry eyes and mouth, impaired pupillary function
 - Enteric – **constipation**, gastroparesis
- Non-pharmacologic measures for orthostatic treatment
 - Compression stockings
 - Abdominal binder
 - Slow positional changes
 - Increasing fluid/salt intake
 - Crossing legs, tip-toeing
- Treatment of AAG
 - Immunomodulatory therapies (IVIg, plasma exchange, mycophenolate mofetil, cyclophosphamide)
 - Fludrocortisone
 - Midodrine
 - Droxidopa

Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial (Neurology 2014)




Figure 3: Mean standing systolic blood pressures in droxidopa trial

REFERENCES

- Lentje JB et al. Evaluation and management of orthostatic hypotension. Am Fam Physician. 2011;84(5): 527-36.
- Melton A and Swamoth EE. Handb Clin Neurol. 2016;133:405-16.
- Palma JK and Kaufman H. New. Clin Clin. Pract. 2017;4(2):208.
- Freeman R. Neurogenic Orthostatic Hypotension. NEJM 2000;35(8):518-24.
- Kaufman H et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;82(4):320-9.
- Nakano S et al. Autoimmune Autonomic Ganglionopathy. Neuroimmunological Diseases 2016. Springer, Tokyo.

TEACHING POINTS

- Always keep a broad differential diagnosis in mind when evaluating a patient with orthostatic hypotension – try to avoid anchoring bias.
- Autoimmune autonomic ganglionopathy (AAG) is a rare cause of autonomic dysfunction associated with +gnAChR antibodies.
- Consider droxidopa for management of refractory neurogenic orthostatic hypotension.